Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2005-10-14
2009-02-03
Zara, Jane (Department: 1635)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C435S006120, C435S091100, C435S091310, C530S300000, C530S324000, C530S350000
Reexamination Certificate
active
07485468
ABSTRACT:
The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
REFERENCES:
patent: WO 03/025148 (2003-03-01), None
patent: WO 2004/094636 (2004-11-01), None
A. Peracchi et al, Rev. Med. Virol., 14:47-64 (2004).
A. Branch, Trends in Biochem. Sci. 23: 45-50 (1998).
S. Crooke, Antisense Res. and Application, Chapter 1, pp. 1-50, (Ed. by S. Crooke) (Publ. Springer-Verlag).
Chirila et al., Biomaterials, 23: 321-342 (2002).
Opalinska et al, Nature Rev., 1: 503-514 (2002).
Agrawal et al, Molecular Med. Today, vol. 6, pp. 82-81 (2000).
Andreakos et al., “Heterogeneous Requirement of IkappaB Kinase 2 for Inflammatory Cytokine and Matrix Metalloproteinase Production in Rheumatoid Arthritis: Implication for Therapy”; Arthritis & Rheumatism, vol. 48, No. 7, pp. 1901-1912 (2003).
Choy and Panayi, “Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis”; N Engl J. Med., 344, No. 12, pp. 907-916 (2001).
Coussens, et al., “Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations”; Science, vol. 295, pp. 2387-2392 (2002).
Creemers, et al., “Matrix Metalloproteinase Inhibition after Myocardial Infarction: A New Approach to Prevent Heart Failure”; Circulation Research, vol. 89(3) pp. 201-210 (2001).
Cunnane, et al., “Early Joint Erosions and Serum Levels of Matrix Metalloproteinase 1, Matrix Metalloprloteinase 3, and Tissue Inhibitor of Metalloproteinases 1 in Rheumatoid Arthritis”; Arthritis & Rheumtism, vol. 44, No. 10, pp. 2263-2274 (2001).
Edwards, et al., “Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients With Rheumatoid Arthritis”; N. Engl. J. Med. 350(25), pp. 2572-2581 (2004).
Firestein, G., “Evolving concepts of rheumatoid arthritis”; Nature 423 , pp. 356-361 (2003).
Gapski, et al., “Effect of Systemic Matrix Metalloproteinase Inhibition on Periodontal Wound Repair: A Proof of Concept Trial”; J. Periodontol. 75(3), pp. 441-452 (2004).
Gomez-Rhino, et al., “Treatment of Rheumatoid ArthritisWith Tumor Necrosis Factor Inhibitors may Predispose to Significant Increase in Tuberculosis Risk: A Multicenter Active-Surveillance Report”; Arthritis Rheumatism, vol. 48, No. 8, pp. 2122-2127 (2003).
Kramer, et al., “Etanercept Added to Background Methotrexate Therapy in Patients with Rheumatoid Arthritis”; Arthritis & Rheumatism, vol. 48, No. 6, pp. 1493-1499 (2003).
Lee and Weinblatt, “Rheumatoid Arthritis”; The Lancet, vol. 358, pp. 903-911 (2001).
O'Dell, “Efficacy of Triple DMARD Therapy in Patients with RA With Suboptimal Response to Methotrexate”; J. of Rheumatology, vol. 23: Suppl. 44, pp. 72-74 (1996).
O'Dell, “Therapeutic Strategies for Rheumatoid Arthritis”; N. Engl. J. Med., 350 (25), pp. 2591-2602 (2004).
Reif, et al., “Matrix Metalloproteinases 2 and 9 are Markers of Inflammation but not of the Degree of Fibrosis in Chromin Hepatitis C”; Digestion, vol. 71, No. 2, pp. 124-130 (2005).
Rosenberg, “Matrix Metalloproteinases in Neuroinflammation”; Glia. 39(3), pp. 279-291 (2002).
Schanstra, et al., “In vivo bradykinin B2 receptor activation reduces renal fibrosis”; J. Clin. Invest., vol. 110, No. 3, pp. 371-391 (2002).
Schett, et al., “Adenovirus-Based Overexpression of Tissue Inhibitor of Metalloproteinases 1 Reduces Tissue Damage in the Joints of Tumor Necrosis Factor α Transgenic Mice”; Arthritis Rheumatism, vol. 44, No. 12, pp. 2888-2898 (2001).
Smolen & Steiner, “Therapeutic Strategies for Rheumatoid Arthritis”; Nature Reviews Drug Discovery, vol. 2 (6) pp. 473-488 (2003).
St. Clair, et al., “Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis: A Randomized, Controlled Trial”; Arthritis Rheumatism, vol. 50, No. 11, pp. 3432-3443 (2004).
Suzuki, et al., “Matrix metalloproteinases in the parthogenesis of asthma and COPD: implications for therapy”; Treat Respir Med., 3(1), pp. 17-27 (2004).
Vincenti, et al, “Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors”; Arthritis Research., vol. 4, No. 3, pp. 157-164 (2002).
Yang, et al, “Modulation of Inflammation and Response to Dexamethasone by Annexin 1 in Antigen-Induced Arthritis”; vol. 50, No. 3, pp. 976-984 (2004).
Brys Reginald
Klaassen Hubertus Johanus Matheus
Tomme Peter Herwig Maria
Vandeghinste Nick
Galapagos BV
Savitzky Martin
Zara Jane
LandOfFree
Molecular targets and compounds, and methods to identify the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular targets and compounds, and methods to identify the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular targets and compounds, and methods to identify the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4140425